Arcutis officer sells shares, receives stock awards

Arcutis Biotherapeutics officer Larry Todd Edwards reported both stock sales and new equity awards.

Rhea-AI Filing Summary

Arcutis Biotherapeutics officer Larry Todd Edwards reported both stock sales and new equity awards. On March 2, 2026, he executed open-market sales totaling 3,687 shares of common stock at weighted average prices around the mid‑$20s per share to cover tax withholding obligations tied to vested restricted stock units.

On February 27, 2026, he received a grant of 77,000 stock options and a separate award of 30,000 restricted stock units, both at a reported price of $0.0000 per share. Following these transactions, his direct common stock holdings were reported at 175,178 shares, and the new options will vest monthly over four years starting March 1, 2026.

Insider Trade Summary

Net Seller: 3,687 shares

Net Sell 4 txns

Insider Edwards Larry Todd

Role See Remarks

Sold 3,687 shs ($93K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,584	$25.161	$90K
Sale	Common Stock	103	$25.9149	$3K
Grant/Award	Stock Option (right to buy)	77,000	$0.00	$0.00
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 77,000 contracts (Direct); Common Stock — 175,178 shares (Direct)

Footnotes (5)

1. F1. Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.
2. F2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
3. F3. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. F5. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

FAQ

What insider transactions did Arcutis (ARQT) report for Larry Todd Edwards?

Arcutis reported that officer Larry Todd Edwards sold 3,687 common shares and received significant new equity awards. The filing shows option and restricted stock unit grants alongside small open-market sales primarily to satisfy tax withholding obligations related to vested RSUs.

How many Arcutis (ARQT) shares did Larry Todd Edwards sell and at what prices?

Larry Todd Edwards sold 3,687 Arcutis common shares in two open-market transactions. Weighted average sale prices ranged from about $24.69 to $26.10 per share, with detailed price breakdowns available on request as noted in the filing’s weighted-average price footnotes.

Why did the Arcutis (ARQT) officer sell 3,687 shares on March 2, 2026?

The 3,687-share sale on March 2, 2026 was made to cover tax withholding obligations from vesting restricted stock units. The filing explicitly states the purpose was withholding-related, indicating these sales were linked to compensation events rather than discretionary portfolio rebalancing.

What new equity awards did Larry Todd Edwards receive from Arcutis (ARQT)?

On February 27, 2026, Larry Todd Edwards was granted 77,000 stock options and 30,000 restricted stock units. The options vest monthly over four years from March 1, 2026, while the RSUs vest 25% annually starting March 1, 2027, contingent on continued service.

How many Arcutis (ARQT) shares does Larry Todd Edwards hold after these transactions?

After the reported transactions, Larry Todd Edwards directly held 175,178 Arcutis common shares. This balance reflects both the acquisition of 30,000 shares via RSU-related award and subsequent 3,687-share sales executed to satisfy associated tax withholding obligations.

How do the new Arcutis (ARQT) stock options for Larry Todd Edwards vest?

The 77,000 stock options granted to Larry Todd Edwards vest in equal monthly installments. One forty-eighth of the options vest each month starting March 1, 2026, so all options become fully vested and exercisable on the fourth anniversary of that vesting commencement date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edwards Larry Todd

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A(1)		30,000	A	$0	178,865	D
Common Stock	03/02/2026		S(2)		3,584	D	$25.161(3)	175,281	D
Common Stock	03/02/2026		S(2)		103	D	$25.9149(4)	175,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.97	02/27/2026		A		77,000		(5)	02/27/2036	Common Stock	77,000	$0	77,000	D

Explanation of Responses:

1. Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

3. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Reporting Person's title: EVP, Chief Commercial Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.